Cargando…

Peroxisome Proliferator-Activated Receptors Family Is Involved in the Response to Treatment and Mild Clinical Course in Patients with Ulcerative Colitis

Background. PPARs play an important role in the regulation of intestinal inflammation. Methods. We included a total of 46 UC patients and 31 controls. The gene expression of PPARs was measured by RT-PCR and protein expression by immunohistochemistry. Results. PPARα gene expression was significantly...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto-Furusho, J. K., Jacintez-Cazares, M., Furuzawa-Carballeda, J., Fonseca-Camarillo, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274912/
https://www.ncbi.nlm.nih.gov/pubmed/25548431
http://dx.doi.org/10.1155/2014/932530
_version_ 1782350062863515648
author Yamamoto-Furusho, J. K.
Jacintez-Cazares, M.
Furuzawa-Carballeda, J.
Fonseca-Camarillo, G.
author_facet Yamamoto-Furusho, J. K.
Jacintez-Cazares, M.
Furuzawa-Carballeda, J.
Fonseca-Camarillo, G.
author_sort Yamamoto-Furusho, J. K.
collection PubMed
description Background. PPARs play an important role in the regulation of intestinal inflammation. Methods. We included a total of 46 UC patients and 31 controls. The gene expression of PPARs was measured by RT-PCR and protein expression by immunohistochemistry. Results. PPARα gene expression was significantly decreased in patients with active UC compared with remission UC group (P = 0.001) and controls (P = 0.001). We found that low gene expression of PPARα in mucosa confers a higher risk of UC activity (P ≤ 0.0001, OR = 22.6). We observed an increase of PPARα expression in patients with UC who were treated with 5-aminosalicylates compared with those who received any other combined therapy (P = 0.03, OR = 0.08). PPARγ gene expression was decreased in the active UC group compared with UC in remission (P = 0.001) and control group (P = 0.001). An increased expression of PPARγ gene was associated with mild clinical course of the disease (P ≤ 0.001, OR = 0.05). No gene expression of PPARβ/δ was found in the colonic mucosa from UC patients and controls. Conclusion. Our results suggest that patients with high gene expression of PPARs have a better response to medical treatment and a mild clinical course of the disease.
format Online
Article
Text
id pubmed-4274912
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-42749122014-12-29 Peroxisome Proliferator-Activated Receptors Family Is Involved in the Response to Treatment and Mild Clinical Course in Patients with Ulcerative Colitis Yamamoto-Furusho, J. K. Jacintez-Cazares, M. Furuzawa-Carballeda, J. Fonseca-Camarillo, G. Dis Markers Research Article Background. PPARs play an important role in the regulation of intestinal inflammation. Methods. We included a total of 46 UC patients and 31 controls. The gene expression of PPARs was measured by RT-PCR and protein expression by immunohistochemistry. Results. PPARα gene expression was significantly decreased in patients with active UC compared with remission UC group (P = 0.001) and controls (P = 0.001). We found that low gene expression of PPARα in mucosa confers a higher risk of UC activity (P ≤ 0.0001, OR = 22.6). We observed an increase of PPARα expression in patients with UC who were treated with 5-aminosalicylates compared with those who received any other combined therapy (P = 0.03, OR = 0.08). PPARγ gene expression was decreased in the active UC group compared with UC in remission (P = 0.001) and control group (P = 0.001). An increased expression of PPARγ gene was associated with mild clinical course of the disease (P ≤ 0.001, OR = 0.05). No gene expression of PPARβ/δ was found in the colonic mucosa from UC patients and controls. Conclusion. Our results suggest that patients with high gene expression of PPARs have a better response to medical treatment and a mild clinical course of the disease. Hindawi Publishing Corporation 2014 2014-12-08 /pmc/articles/PMC4274912/ /pubmed/25548431 http://dx.doi.org/10.1155/2014/932530 Text en Copyright © 2014 J. K. Yamamoto-Furusho et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Yamamoto-Furusho, J. K.
Jacintez-Cazares, M.
Furuzawa-Carballeda, J.
Fonseca-Camarillo, G.
Peroxisome Proliferator-Activated Receptors Family Is Involved in the Response to Treatment and Mild Clinical Course in Patients with Ulcerative Colitis
title Peroxisome Proliferator-Activated Receptors Family Is Involved in the Response to Treatment and Mild Clinical Course in Patients with Ulcerative Colitis
title_full Peroxisome Proliferator-Activated Receptors Family Is Involved in the Response to Treatment and Mild Clinical Course in Patients with Ulcerative Colitis
title_fullStr Peroxisome Proliferator-Activated Receptors Family Is Involved in the Response to Treatment and Mild Clinical Course in Patients with Ulcerative Colitis
title_full_unstemmed Peroxisome Proliferator-Activated Receptors Family Is Involved in the Response to Treatment and Mild Clinical Course in Patients with Ulcerative Colitis
title_short Peroxisome Proliferator-Activated Receptors Family Is Involved in the Response to Treatment and Mild Clinical Course in Patients with Ulcerative Colitis
title_sort peroxisome proliferator-activated receptors family is involved in the response to treatment and mild clinical course in patients with ulcerative colitis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274912/
https://www.ncbi.nlm.nih.gov/pubmed/25548431
http://dx.doi.org/10.1155/2014/932530
work_keys_str_mv AT yamamotofurushojk peroxisomeproliferatoractivatedreceptorsfamilyisinvolvedintheresponsetotreatmentandmildclinicalcourseinpatientswithulcerativecolitis
AT jacintezcazaresm peroxisomeproliferatoractivatedreceptorsfamilyisinvolvedintheresponsetotreatmentandmildclinicalcourseinpatientswithulcerativecolitis
AT furuzawacarballedaj peroxisomeproliferatoractivatedreceptorsfamilyisinvolvedintheresponsetotreatmentandmildclinicalcourseinpatientswithulcerativecolitis
AT fonsecacamarillog peroxisomeproliferatoractivatedreceptorsfamilyisinvolvedintheresponsetotreatmentandmildclinicalcourseinpatientswithulcerativecolitis